Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Primary Care
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
Related Questions
For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
How would you manage a patient with metastatic hormone sensitive prostate cancer who received docetaxel but has toxicity while on darolutamide (+ leuprolide)??
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
What are your top takeaways in GU Cancers from ESMO 2025?
For patients starting Pluvicto, do you have patients stop their ARPI?
